Just to explain why this evidence is highly insufficient to translate to HL pts. They used Karpas injections in NSG mice, which is basically to show the CD30/CD16a engagement, but this so far off a solid-like tumor like HL w/ a existent TME. No wonder AFM
These are the key figures, they based their AFM13 loading thesis on, Karpas (btw NHL cell line!) in NSG mice! from co presentation and Rezvani paper https://t.co/FWcyOqQ4H3 https://t.co/VV7wi8qeRL
@dhovekamp42 Yes, but what's Artiva's expansion protocol. Rezvani credits persistence to preactivation w/cocktail of IL 12/15/18 to induce memory pheno-t. GC Cell's patent suggests cocktail (alone?) not proliferative enough for commercial scale. Hard to t
@NK_papers Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies https://t.co/lCQqAABnwx
@Andre_AGTC @Biotech2k1 Part of the effect is from the right NK cell. AFM13 contributes as well. This paper might help. https://t.co/C37IuzKwWj https://t.co/oPuEKrf9ED
@BrianUherek We dont know for sure, but the cb derived NK expansion protocol (based on GC Cell patents, which Artiva uses) looks quite similar to the MD Anderson one. GC Cell NK expansion (one of them) https://t.co/skO07Qt5bU Rezvani paper u know https://t
RT @BroeckelmannPJ: AFM13 + pembrolizumab @BloodJournal: https://t.co/T6BUHdvSns AFM13 + cord-blood NK cells @CCR_AACR: https://t.co/2QLr8…
RT @BroeckelmannPJ: AFM13 + pembrolizumab @BloodJournal: https://t.co/T6BUHdvSns AFM13 + cord-blood NK cells @CCR_AACR: https://t.co/2QLr8…
AFM13 + pembrolizumab @BloodJournal: https://t.co/T6BUHdvSns AFM13 + cord-blood NK cells @CCR_AACR: https://t.co/2QLr8Pu8g2 Dose schedules investigated in the GHSG trial below. Of note, highest trough levels and ORR (2/8 pts) observed with continuous inf
@Biotech2k1 @JamesPe11062557 @timvantreuren https://t.co/wFWruq8gVp Don't see any gene editing unlike the CAR-NK therapy in your screenshot. They just preactivate and expand these NK cells, no editing. Really don't think these are comparable
@BrianUherek @PhilippBaer1 Seen any good research on development of SNK01 by NKGen? Something like Kerbauy, et al last year. @lucila_kerbauy https://t.co/j3PoOPtRTz
RT @Marlowe_Tessmer: Watching Dr. Yago Nieto present data from -Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated B…
Watching Dr. Yago Nieto present data from -Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies #AACR22 https://t.co/SHB0zYgFVO https://t.
RT @8thKingofRome: $AFMD AFM13+cbNK figures uploaded on https://t.co/GlABGfBtEi
RT @8thKingofRome: $AFMD AFM13+cbNK figures uploaded on https://t.co/GlABGfBtEi
RT @8thKingofRome: $AFMD AFM13+cbNK figures uploaded on https://t.co/GlABGfBtEi
RT @8thKingofRome: $AFMD AFM13+cbNK figures uploaded on https://t.co/GlABGfBtEi
RT @8thKingofRome: $AFMD AFM13+cbNK figures uploaded on https://t.co/GlABGfBtEi
RT @8thKingofRome: $AFMD AFM13+cbNK figures uploaded on https://t.co/GlABGfBtEi
$AFMD AFM13+cbNK figures uploaded on https://t.co/GlABGfBtEi
RT @CellworksLife: AFM13 as a promising combination with cytokine-activated adult blood or cord-blood NK cells to treat CD30+ hematologic m…
AFM13 as a promising combination with cytokine-activated adult blood or cord-blood NK cells to treat CD30+ hematologic malignancies. #HemeCancer #CombinationTherapy https://t.co/kAihJl64bC
$AFMD ( Thx @8thKingofRome )
RT @CancerCureNow: Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilita…
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies https://t.co/S94vyNuuyC
RT @Cord_Blood_News: The combination of AFM13 and IL-12/15/18 pre-activation of blood and #CordBlood-derived natural killer cells was inves…
RT @Cord_Blood_News: The combination of AFM13 and IL-12/15/18 pre-activation of blood and #CordBlood-derived natural killer cells was inves…
RT @Cord_Blood_News: The combination of AFM13 and IL-12/15/18 pre-activation of blood and #CordBlood-derived natural killer cells was inves…
RT @Cord_Blood_News: The combination of AFM13 and IL-12/15/18 pre-activation of blood and #CordBlood-derived natural killer cells was inves…
The combination of AFM13 and IL-12/15/18 pre-activation of blood and #CordBlood-derived natural killer cells was investigated in vitro and in vivo. @CCR_AACR: https://t.co/07eD9wUsSO https://t.co/AEu8DFiKyb
$afmd https://t.co/uv0edQEPeA
RT @Transplant_Doc: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-l…
RT @Transplant_Doc: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-l…
RT @RNAiAnalyst: $AFMD from the recent publication. Seems to favor off-the-shelf allogeneic solution as NK cell source endgame: https://t.…
RT @RNAiAnalyst: $AFMD from the recent publication. Seems to favor off-the-shelf allogeneic solution as NK cell source endgame: https://t.…
$AFMD from the recent publication. Seems to favor off-the-shelf allogeneic solution as NK cell source endgame: https://t.co/n71cGmTurE https://t.co/B9dhFXTvEq
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
Latest piece followed by a list of related articles - Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates C… https://t.co/np4IT9NRrY
RT @weldeiry: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like re…
$afmd
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies | Clinical Cancer Research https://t.co/HFgrGZSPzp
RT @JBrosnanCashman: Now online in @CCR_AACR: Work from @lab_rezvani and @LabFehniger reveals enhanced efficacy of AFM13, a bispecific CD30…
RT @JBrosnanCashman: Now online in @CCR_AACR: Work from @lab_rezvani and @LabFehniger reveals enhanced efficacy of AFM13, a bispecific CD30…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @Transplant_Doc: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-l…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @Transplant_Doc: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-l…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies @lucila_kerbauy @EJShpallMD @lab_rezvani @MDAndersonNews #NKcell #CellTherapy #bmtsm https://t
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies https://t.co/7UJRpMtiGO
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies by Lucila N Kerbauy https://t.co/8JtasvQ4uR
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies #lymphoma #lymsm https://t.co/DUUWt7i7cH
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies https://t.co/gKq9XXoED8
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @JBrosnanCashman: Now online in @CCR_AACR: Work from @lab_rezvani and @LabFehniger reveals enhanced efficacy of AFM13, a bispecific CD30…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
RT @lab_rezvani: Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Gr…
Please check out our paper on #NK cells precomplexed with AFM13 enhancing NK activity against CD30+ lymphoma @ccr_aacr. Great collaboration with @LabFehniger. Congrats @lucila_kerbauy & Nancy. This preclinical work is the rationale for our ongoing clin
RT @JBrosnanCashman: Now online in @CCR_AACR: Work from @lab_rezvani and @LabFehniger reveals enhanced efficacy of AFM13, a bispecific CD30…
RT @Aenoreth: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like re…
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies https://t.co/CYo6o0t9Ht
RT @8thKingofRome: Here the new preclinical findings published on AACR journal of #AFM13 + cbNK $AFMD https://t.co/2BF9A3Vqmg
Now online in @CCR_AACR: Work from @lab_rezvani and @LabFehniger reveals enhanced efficacy of AFM13, a bispecific CD30/CD16 antibody, when combined with cytokine-activated #NKcells in #lymphoma. @MDAndersonNews @SitemanCenter https://t.co/msEzFpXpH5
RT @DraettaG: Novel approach reported by Katy Rezvani and colleagues: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activ…
Novel approach reported by Katy Rezvani and colleagues: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies https://t.co/SWpjE5iOJ9
RT @8thKingofRome: Here the new preclinical findings published on AACR journal of #AFM13 + cbNK $AFMD https://t.co/2BF9A3Vqmg
Here the new preclinical findings published on AACR journal of #AFM13 + cbNK $AFMD https://t.co/2BF9A3Vqmg